COMPENDIUM ON FUNCTIONAL MEDICINE - Flipbook - Page 785
[25] Miquel S, Martín R, Rossi O, et al. Faecalibacterium prausnitzii
and human intestinal health. Curr Opin Microbiol.
2013;16(3):255-61.
[26] Quévrain E, Maubert MA, Michon C, et al. Identification of an
anti-inflammatory protein from Faecalibacterium prausnitzii, a
commensal bacterium deficient in Crohn's disease. Gut.
2016;65(3):415-25.
[27] Martín R, Miquel S, Chain F, et al. Faecalibacterium prausnitzii
prevents physiological damages in a chronic low-grade
inflammation murine model. BMC Microbiol. 2015;15:67.
[28] Furusawa Y, Obata Y, Fukuda S, et al. Commensal
microbe-derived butyrate induces the differentiation of colonic
regulatory T cells. Nature. 2013;504(7480):446-50.
[29] Kelly CJ, Zheng L, Campbell EL, et al. Crosstalk between
microbiota-derived short-chain fatty acids and intestinal epithelial
HIF augments tissue barrier function. Cell Host Microbe.
2015;17(5):662-71.
[30] Ferreira-Halder CV, Faria AVS, Andrade SS. Action and
function of Faecalibacterium prausnitzii in health and disease. Best
Pract Res Clin Gastroenterol. 2017;31(6):643-648.
[31] Machiels K, Joossens M, Sabino J, et al. A decrease of the
butyrate-producing species Roseburia hominis and
Faecalibacterium prausnitzii defines dysbiosis in patients with
ulcerative colitis. Gut. 2014;63(8):1275-83.
[32] Mori G, Rampelli S, Orena BS, et al. Shifts of faecal microbiota
during sporadic colorectal carcinogenesis. Sci Rep.
2018;8(1):10329.
[33] Pozuelo M, Panda S, Santiago A, et al. Reduction of butyrateand methane-producing microorganisms in patients with irritable
bowel syndrome. Sci Rep. 2015;5:12693.
785
